Cannabiz Australia report that Canadian cannabis company MPX International won’t be investing in a $8m indoor cultivation facility in the island state.
This story is a must read as it is indicative of everything that is currently wrong with regulated manufacturing of medical cannabis in Australia. Overpriced political connections for the board being just one of the myriad of issues
Announcing its Q3 2020 financial results, the company said: “In Australia, the opportunity to import products from Malta, Canada and South Africa has prompted the corporation to change its focus from domestic production to developing an import and distribution capability and now plans to import and introduce the Salus branded products to the Australian market.
Read the full story
MPX International ditches plans for Tasmanian growing facility
